WO2003000118A2 - Method for enhancing the effectiveness of cancer therapies - Google Patents

Method for enhancing the effectiveness of cancer therapies Download PDF

Info

Publication number
WO2003000118A2
WO2003000118A2 PCT/US2002/019885 US0219885W WO03000118A2 WO 2003000118 A2 WO2003000118 A2 WO 2003000118A2 US 0219885 W US0219885 W US 0219885W WO 03000118 A2 WO03000118 A2 WO 03000118A2
Authority
WO
WIPO (PCT)
Prior art keywords
compound
patient
administering
galectin
modified pectin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2002/019885
Other languages
English (en)
French (fr)
Other versions
WO2003000118A3 (en
Inventor
Yang Chang
Vodek Sasek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlycoGenesys Inc
Original Assignee
GlycoGenesys Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlycoGenesys Inc filed Critical GlycoGenesys Inc
Priority to CA002451841A priority Critical patent/CA2451841A1/en
Priority to AU2002320140A priority patent/AU2002320140B2/en
Priority to EP02749641A priority patent/EP1406639A4/en
Priority to MXPA03012021A priority patent/MXPA03012021A/es
Priority to JP2003506572A priority patent/JP2004535430A/ja
Priority to IL15946102A priority patent/IL159461A0/xx
Priority to BR0210550-0A priority patent/BR0210550A/pt
Publication of WO2003000118A2 publication Critical patent/WO2003000118A2/en
Publication of WO2003000118A3 publication Critical patent/WO2003000118A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/732—Pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

  • Galectins comprise a family of proteins which are expressed by plant and animal cells and which bind ⁇ -galactoside sugars. These proteins can be found on cell surfaces, in cytoplasm, and in extracellular fluids. They have a molecular weight in the general range of 29-34 kD; they have an affinity for ⁇ - galactoside containing materials, and have been found to play a number of important roles in biological processes including cell migration, cell-cell adhesion, angiogenesis, cell fusion and other cell-cell interactions, as well as immune-based reactions and apoptosis. As such, the role of galectins is very strongly tied to cancer and other proliferative diseases.
  • the treatment being enhanced may comprise chemotherapy, radiation therapy, surgery and combinations thereof.
  • the method of the present invention comprises administering to a patient a therapeutically effective amount of a compound which binds to a galectin. This compound may be administered prior to, after, or concomitant with the other treatment.
  • U.S. Patent 5,895,784 the disclosure of which is incorporated herein by reference, describes modified pectin materials, techniques for their preparation, and use of the material as a treatment for various cancers.
  • the material of the '784 patent is described as being prepared by a pH based modification procedure in which the pectin is put into solution and exposed to a series of programmed changes in pH which results in the breakdown of the molecule to yield therapeutically effective modified pectin.
  • the material in the '784 patent is most preferably prepared from citrus pectin; although, it is to be understood that modified pectins may be prepared from pectin starting material obtained from other sources, such as apple pectin and the like.
  • a galectin binding therapeutic material is administered to a patient, in combination with conventional therapies such as surgery, radiation or chemotherapy.
  • the material is most preferably administered prior to the administration ofthe conventional therapy, so as to allow it sufficient time to interact with and bind to galectins in the tumor or in non-cancerous cells.
  • administration of the galectin binding therapeutic material may be continued while the other therapy is being administered and/or thereafter.
  • Administration of the galectin binding material may be made in a single dose, or in multiple doses.
  • administration of the therapeutic material is commenced at least several days prior to the conventional therapy, while in other instances, administration is begun either immediately before or at the time of the administration of the conventional therapy.
  • the carbohydrate material may be advantageously administered both before, during and after the therapy.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
PCT/US2002/019885 2001-06-21 2002-06-21 Method for enhancing the effectiveness of cancer therapies Ceased WO2003000118A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA002451841A CA2451841A1 (en) 2001-06-21 2002-06-21 Method for enhancing the effectiveness of cancer therapies
AU2002320140A AU2002320140B2 (en) 2001-06-21 2002-06-21 Method for enhancing the effectiveness of cancer therapies
EP02749641A EP1406639A4 (en) 2001-06-21 2002-06-21 IMPROVING THE EFFECTIVENESS OF CANCER THERAPIES
MXPA03012021A MXPA03012021A (es) 2001-06-21 2002-06-21 Metodo para mejorar la efectividad de las terapias contra el cancer.
JP2003506572A JP2004535430A (ja) 2001-06-21 2002-06-21 癌治療の有効性を向上させる方法
IL15946102A IL159461A0 (en) 2001-06-21 2002-06-21 Method for enhancing the effectiveness of cancer therapies
BR0210550-0A BR0210550A (pt) 2001-06-21 2002-06-21 Método para realçar a eficácia de terapias contra o câncer

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US29999101P 2001-06-21 2001-06-21
US60/299,991 2001-06-21
US10/176,235 2002-06-20
US10/176,235 US6680306B2 (en) 2001-06-21 2002-06-20 Method for enhancing the effectiveness of cancer therapies

Publications (2)

Publication Number Publication Date
WO2003000118A2 true WO2003000118A2 (en) 2003-01-03
WO2003000118A3 WO2003000118A3 (en) 2003-04-10

Family

ID=26872020

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2002/019885 Ceased WO2003000118A2 (en) 2001-06-21 2002-06-21 Method for enhancing the effectiveness of cancer therapies

Country Status (11)

Country Link
US (3) US6680306B2 (https=)
EP (1) EP1406639A4 (https=)
JP (1) JP2004535430A (https=)
CN (1) CN100558367C (https=)
AU (1) AU2002320140B2 (https=)
BR (1) BR0210550A (https=)
CA (1) CA2451841A1 (https=)
CZ (1) CZ200487A3 (https=)
IL (1) IL159461A0 (https=)
MX (1) MXPA03012021A (https=)
WO (1) WO2003000118A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006522163A (ja) * 2003-04-07 2006-09-28 グリコジェネシス， インク． ガレクチンアンタゴニストの組成物と使用
US7893252B2 (en) 2003-09-08 2011-02-22 Pro-Pharmaceuticals, Inc. Selectively depolymerized galactomannan polysaccharide

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL157443A0 (en) * 2001-03-14 2004-03-28 Bristol Myers Squibb Co Pharmaceutical compositions for the treatment of cancer including an epothilone analog and a chemotherapeutic agent
US6680306B2 (en) * 2001-06-21 2004-01-20 Glycogenesys, Inc. Method for enhancing the effectiveness of cancer therapies
US20030004132A1 (en) * 2001-06-22 2003-01-02 Yan Chang Method and material for treating immune diseases
US6890906B2 (en) 2001-11-21 2005-05-10 Glycogenesys, Inc. Method for controlling angiogenesis in animals
US20040121981A1 (en) * 2001-11-21 2004-06-24 Glycogenesys, Inc. Method for controlling angiogenesis in animals
US20040259816A1 (en) * 2002-10-01 2004-12-23 Pandol Stephen J. Compositions comprising plant-derived polyphenolic compounds and inhibitors of reactive oxygen species and methods of using thereof
US20040223971A1 (en) * 2003-04-07 2004-11-11 Glycogenesys, Inc. Composition and uses of galectin antagonists
WO2005007110A2 (en) * 2003-07-11 2005-01-27 Pro-Pharmaceuticals, Inc. Compositions and methods for hydrophobic drug delivery
DE10335236B3 (de) * 2003-08-01 2005-02-24 Drägerwerk AG Messsystem für die Bestimmung der Konzentration von Propofol (2,6-Diisopropylphenol) im Atemstrom
EP2591786B1 (en) 2003-10-16 2017-04-12 Cancure Limited Immunomodulating compositions and uses therefor
US20050282773A1 (en) * 2004-01-14 2005-12-22 Pro-Pharmaceuticals, Inc. Modified polysaccharides in combination with anti-cancer drugs for enhanced treatment of cancer
EP1718146A2 (en) * 2004-02-13 2006-11-08 Pro-Pharmaceuticals, Inc. Compositions and methods used to treat acne and candida
WO2005095463A1 (en) 2004-03-26 2005-10-13 Glycogenesys, Inc. Modified pectins, compositions and methods related thereto
WO2006020027A1 (en) * 2004-07-14 2006-02-23 Glycogenesys, Inc. Composition and method for treating hyperproliferative diseases
US20080286251A1 (en) * 2004-08-02 2008-11-20 Propharmaceuticals, Inc. Compositions and Methods for the Enhancement of Chemotherapy with Microbial Cytotoxins
MX2007011767A (es) * 2005-03-23 2007-10-18 Pfizer Prod Inc Terapia de combinacion de anticuerpo anti-ctla4 e indolinona para el tratamiento del cancer.
US8221803B1 (en) 2007-06-25 2012-07-17 OncoNatural Solutions, Inc. Composition for prostate health
EP2184997A4 (en) * 2007-07-31 2010-11-03 Univ New York DIAGNOSIS AND TREATMENT METHODS FOR THE CHARACTERIZATION OF BACTERIAL MICROORGANISMS IN SKIN DISEASES
CA3061784C (en) 2009-11-13 2023-09-26 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1
ES2669068T3 (es) * 2011-12-08 2018-05-23 Eliaz Therapeutics, Inc Reducción de niveles de galectina-3 mediante plasmaféresis
MX363923B (es) * 2011-12-28 2019-04-08 Galectin Therapeutics Inc Composicion de farmaco de carbohidrato novedoso para el tratamiento de enfermedades humanas.
WO2013152313A1 (en) * 2012-04-05 2013-10-10 The Regents Of The University Of California Compositions and methods for treating cancer and diseases and conditions responsive to growth factor inhibition
CA2875979C (en) 2012-06-06 2021-01-26 Galectin Therapeutics, Inc. Galacto-rhamnogalacturonate compositions for the treatment of diseases associated with elevated inducible nitric oxide synthase
AU2013315019B2 (en) 2012-09-17 2017-06-01 Galectin Therapeutics, Inc. Method for enhancing specific immunotherapies in cancer treatment
DK2906227T3 (en) 2012-10-10 2018-12-10 Galectin Therapeutics Inc GALACTOSE-CONTAINING CARBOHYDRATE COMPOUNDS FOR THE TREATMENT OF DIABETIC Nephropathy
US9339515B2 (en) 2013-02-20 2016-05-17 Galectin Therapeutics, Inc. Method for treatment of pulmonary fibrosis
CA2930817A1 (en) 2013-11-17 2015-05-21 Rdd Pharma Ltd. Methods for treating radiation induced gastrointestinal tract injury
CA3031691A1 (en) * 2016-09-13 2018-03-22 Rasna Research Inc. Dactinomycin compositions and methods for the treatment of myelodysplastic syndrome and acute myeloid leukemia
EP3621973A4 (en) 2017-05-12 2021-10-27 Galectin Sciences, LLC COMPOUNDS FOR THE PREVENTION AND TREATMENT OF DISEASES AND USES THEREOF
WO2020136650A1 (en) 2018-12-25 2020-07-02 Sol-Gel Technologies Ltd. Treatment of skin disorders with compositions comprising an egfr inhibitor

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US107222A (en) * 1870-09-13 Improvement in machines for tenoning window-sash
US5490991A (en) 1986-07-03 1996-02-13 Advanced Magnetics, Inc. Directed delivery of radioprotectants using a receptor specific carrier
US5843442A (en) 1990-10-22 1998-12-01 Corvas International, Inc. Blood coagulation protein antagonists and uses therefor
US5639737A (en) 1991-11-04 1997-06-17 Co Enzyme Technology Ltd. Method and compositions for treating malignant tumors and inhibiting growth and metastases of malignant tumors
US20020107222A1 (en) 1993-03-01 2002-08-08 David Platt Modified polysaccharides for treatment of cancer
US5490911A (en) * 1993-11-26 1996-02-13 The United States Of America As Represented By The Department Of Energy Reactive multilayer synthesis of hard ceramic foils and films
US5498702A (en) * 1993-12-16 1996-03-12 California Natural Products Treated pectinic acid process and product
US5834442A (en) 1994-07-07 1998-11-10 Barbara Ann Karmanos Cancer Institute Method for inhibiting cancer metastasis by oral administration of soluble modified citrus pectin
US5681923A (en) 1995-10-06 1997-10-28 Platt; David Tumor derived carbohydrate binding protein
WO1997033593A1 (en) * 1996-03-15 1997-09-18 Takara Shuzo Co., Ltd. A product of heat treatment of uronic acid, food, drink or drug including the product
US5831052A (en) * 1997-05-07 1998-11-03 Incyte Pharmaceuticals, Inc. New human translocation associated protein
US6875451B2 (en) * 1997-10-15 2005-04-05 Polarx Biopharmaceuticals Inc. Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds
US6258383B1 (en) * 1998-08-14 2001-07-10 Lactoferrin Products Company Dietary supplement combining colostrum and lactoferrin in a mucosal delivery format
US6500807B1 (en) * 1999-02-02 2002-12-31 Safescience, Inc. Modified pectin and nucleic acid composition
US6274566B1 (en) * 1999-02-23 2001-08-14 Econugenics, Inc. Methods for treating mammals with modified alginates and pectins
EP1363673A2 (en) * 2000-09-25 2003-11-26 Pro-Pharmaceuticals, Inc. Compositions for reducing side effects in chemotherapeutic treatments
US20020104222A1 (en) * 2001-02-06 2002-08-08 Jay Larry Dean Knife for removing the hide of an animal and method therefor
US7012068B2 (en) * 2001-03-27 2006-03-14 Pro-Pharmaceuticals, Inc. Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer
US6982255B2 (en) * 2001-03-27 2006-01-03 Anatole Klyosov Delivery of a therapeutic agent in a formulation for reduced toxicity
US6914055B2 (en) * 2001-03-27 2005-07-05 Anatole Klyosov Delivery of a therapeutic agent in a formulation for reduced toxicity
US6645946B1 (en) * 2001-03-27 2003-11-11 Pro-Pharmaceuticals, Inc. Delivery of a therapeutic agent in a formulation for reduced toxicity
US6680306B2 (en) * 2001-06-21 2004-01-20 Glycogenesys, Inc. Method for enhancing the effectiveness of cancer therapies
US20040223971A1 (en) * 2003-04-07 2004-11-11 Glycogenesys, Inc. Composition and uses of galectin antagonists
WO2006020027A1 (en) * 2004-07-14 2006-02-23 Glycogenesys, Inc. Composition and method for treating hyperproliferative diseases

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006522163A (ja) * 2003-04-07 2006-09-28 グリコジェネシス， インク． ガレクチンアンタゴニストの組成物と使用
EP1980257A1 (en) 2003-04-07 2008-10-15 Prospect Therapeutics, Inc. Compositions and uses of galectin antagonists
US7893252B2 (en) 2003-09-08 2011-02-22 Pro-Pharmaceuticals, Inc. Selectively depolymerized galactomannan polysaccharide

Also Published As

Publication number Publication date
BR0210550A (pt) 2004-05-25
AU2002320140B2 (en) 2007-11-29
CA2451841A1 (en) 2003-01-03
MXPA03012021A (es) 2004-06-03
US20040023925A1 (en) 2004-02-05
US20040043962A1 (en) 2004-03-04
CN100558367C (zh) 2009-11-11
US20030013681A1 (en) 2003-01-16
CN1543351A (zh) 2004-11-03
JP2004535430A (ja) 2004-11-25
IL159461A0 (en) 2004-06-01
US6680306B2 (en) 2004-01-20
WO2003000118A3 (en) 2003-04-10
EP1406639A2 (en) 2004-04-14
EP1406639A4 (en) 2004-07-28
CZ200487A3 (cs) 2004-10-13

Similar Documents

Publication Publication Date Title
US6680306B2 (en) Method for enhancing the effectiveness of cancer therapies
AU2002320140A1 (en) Method for enhancing the effectiveness of cancer therapies
Wang et al. Osthole induces cell cycle arrest and inhibits migration and invasion via PTEN/Akt pathways in osteosarcoma
US20140148404A1 (en) Composition and uses of galectin antagonists
JP5484320B2 (ja) ナリンゲニンとナリンジンを形質転換成長因子−β１のシグナル経路阻害剤とする使用
EP1617849B1 (en) Composition and uses of galectin antagonists
Ma et al. Ferulic acid attenuates adhesion molecule expression in gamma-radiated human umbilical vascular endothelial cells
Tyczyńska et al. Treatment strategies of gastric cancer—Molecular targets for anti-angiogenic therapy: A state-of-the-art review
CN100558368C (zh) 化合物在制备用于治疗免疫性疾病的药物中的用途
CN108186643B (zh) 一种具有协同抗骨肉瘤功效的药物组合物及其应用
AU2012281131B2 (en) Novel zinc finger-like peptide compositions as potent agents in cancer prevention and treatment
WO2000056334A1 (en) Use of imino sugars for anti-tumor therapy
IL131096A0 (en) Muscle-derived compositions
Amagase et al. Epidermal growth factor receptor‐mediated selective cytotoxicity of antitumor agents toward human xenografts and murine syngeneic solid tumors
US10328056B2 (en) Priming of pancreatic tumor cells and cancer stem cells to TRAIL-induced apoptosis
Piovella et al. Clinical experience of nadroparin in patients with cancer
CN110876803B (zh) 一种包含乳蛋白和油酸的药物组合物
Uhlenbruck et al. Prevention of experimental liver metastases by D-galactose
Sonwani When Anticancer Agents Are Applied to Adenocarcinoma Cells, Platelets Improve Their Survival Rate Medications: Mechanisms and Chemoresistance Implications
KR102065150B1 (ko) 이소트레티노인-펩타이드 결합체를 유효성분으로 포함하는 비만의 예방 또는 치료용 조성물
WO2015184248A1 (en) Methods of treating fibrotic diseases
정성우 Design and development of multi-targeted anticancer agents for anti-angiogenic therapy or tumor tissue-selective delivery
Lamoureux et al. Therapeutic efficacy of soluble receptor activator of NF-kB (RANK) delivered by non viral gene transfer in a mouse model of osteolytic osteosarcoma
AU2002320141A1 (en) Method and material for treating immune diseases

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2451841

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 159461

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2003506572

Country of ref document: JP

Ref document number: PA/a/2003/012021

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2227/DELNP/2003

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 530345

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2002320140

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: PV2004-87

Country of ref document: CZ

WWE Wipo information: entry into national phase

Ref document number: 2002749641

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 20028160037

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2002749641

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: PV2004-87

Country of ref document: CZ

ENP Entry into the national phase

Ref document number: 2002320140

Country of ref document: AU

Date of ref document: 20020621

Kind code of ref document: B